Introduction. Atrial fibrillation (AF) per se causes atrial endocardial dysfunction leading to local coagulation imbalance on the internal surface of the atrium, which contributes to thrombus formation in the fibrillating left atrium. Materials and methods. To test a hypothesis that blockade of angiotensin II type 1 receptor (AT 1 -receptor) prevents the endocardial dysfunction by AF, we examined the effects of olmesartan on the expression of tissue factor pathway inhibitor (TFPI), thrombomodulin (TM), endothelial nitric oxide synthase (eNOS) and plasminogen activator inhibitor-1 (PAI-1) in the endocardium of the rapidly paced rat atria. Results. Rapid pacing induced a significant decrease in TFPI,TM and eNOS and an increase in PAI-1 protein in the left atrium. Pre-administration of low-dose olmesartan significantly prevented the down-regulation of TFPI,TM and eNOS and also attenuated the up-regulation of PAI-1. Immunohistochemistry identified these changes predominantly in the atrial endocardium.While the drug was without any effect on mRNA levels of TFPI,TM and eNOS, there was a significant decrease in its PAI-1 mRNA expression. Conclusions. AT 1 -receptor blocker could partially prevent the atrial endocardial dysfunction by rapid atrial pacing, which would provide one theoretical basis for beneficial effects for stroke prevention in AF.
Introduction
Atrial fibrillation (AF), the most common type of arrhythmia in adults, is associated with a five-fold increase in the incidence of ischaemic stroke. 1, 2 Most strokes in AF patients, one of the major reasons for hospitalisation in this group, 3 are believed to be cardioembolic, caused by embolism of left atrial thrombi. 4 Thrombus formation in the left atrium could result from decrease in blood flow, 5 increase in blood coagulability, 6 and also endocardial dysfunction in the left atrium. 7 Several recent experimental reports including ours have demonstrated that AF per se causes atrial endocardial dysfunction, which is manifested by reduced endothelial nitric oxide synthase (eNOS), increased expression of plasminogen inhibitor-1 (PAI-1) and also decreased expression of tissue factor pathway inhibitor (TFPI) and thrombomodulin (TM) in the left atrial endocardium, leading to local coagulation imbalance on the internal surface of the atrium. 8, 9 Oral anticoagulation is well known to be highly effective in preventing stroke in AF patients. 10 Moreover, recent clinical studies concerning AF have demonstrated that a new modality, blockade of the renin-angiotensin system (RAS), might be also effective as an adjuvant therapy. 11, 12 In the Losartan Intervention For End point reduction in hypertension (LIFE) study, losartan significantly decreased the number of strokes compared with atenolol in AF patients with hypertension and left ventricular hypertrophy. 11 Also, in the Perindopril Protection Against Recurrent Stroke (PROGRESS) study, perindopril decreased stroke in AF patients with a history of cerebrovascular events. 12 Interestingly, these preventive effects were independent of the blood pressure (BP) and oral anticoagulation, proposing a new hypothesis that RASs are involved in the left atrial thrombus formation through an unknown process. To test this hypothesis, we examined the effects of olmesartan, an angiotensin II type 1 blocker (ARB), 13 on the endocardial dysfunction caused by atrial tachycardia in rats.
Material and methods

Preparation of atrial tachycardia models
Sprague-Dawley rats aged 12 weeks were used in the present study. The atrial tachycardia rat model was prepared as shown in our previous study. 14 Briefly, a quadripolar electrode catheter (1.5 Fr) was introduced through the cervical vein for pacing and recording in anaesthetised rats. Stimulation at a frequency of 1,200 bpm was performed with 2-ms rectangular pulses using a programmable stimulator and a constant current source (SEN 7203 and SS401J, Nihon Kohden). Sham-operated animals underwent an identical procedure without stimulation. Hearts were removed after eight-hour pacing, the left atrial appendages removed within 30 seconds and the material for ribonucleic acid (RNA) and protein analysis immediately frozen in liquid nitrogen. were prepared by reverse transcript polymerase chain reaction (RT-PCR) (Access RT-PCR system, Promega) from total RNA isolated from the rat atrium. The amplified cDNA fragments were subcloned into PCR II vectors (Invitrogen) and confirmed by sequencing. The primers specific for tissue factor pathway inhibitor (TFPI) and TM were shown in our previous study 9 and those for eNOS and PAI-1 based on the known sequence were: forward primer 5´-CAGCATCACCTACGATACCCTCAGTG-3´and inverse primer 5´-CAGCTCA-CTCTCCCGGAGCTGGTAGG-3f or eNOS; forward primer 5´-ATGAGATCAGTACT-GCGGACGCCATC-3´and inverse primer 5´-GGGCGTTCACCAGCACCAGGCGTGTC-3´for PAI-1. These plasmids were used to synthesise the antisense digoxigenin-labelled RNA probes.
Preparation of DNA templates
RNA preparation and ribonuclease (RNase) protection assay
The levels of the mRNAs were assayed using the RNase protection assay with RPA III kit (Ambion), as described previously. 9 Chemiluminescent signals were quantified using the lumino-image analyser (ATTO LightCapture AE-6960, ATTO). The cyclophilin signals were used as internal control.
Western blot analysis and immunohistochemistry
Total proteins (30 μg) extracted from the left atrial appendages were fractionated on SDS-PAGE gels and transferred to PVDF membranes (Boehringer Mannheim). The membrane was incubated with polyclonal anti-TFPI (The Chemo-Sero-Therapeutic Reseach Institute), anti-TM (American Diagnostica Inc.), anti-eNOS (BD Bioscience Pharmingen), and anti-PAI-1 antibody (American Diagnostica Inc.) obtained from rabbit and subsequently with goat anti-rabbit immunoglobulin G conjugated to alkalinephosphatase (Boehringer Mannheim). The immunohistochemistry was performed in cryostat sections (8 μm-thick) by the simple stain Western blot of tissue factor pathway inhibitor (TFPI), thrombomodulin (TM), endothelial nitric oxide sythase (eNOS) and plasminogen activator inhibitor-1 (PAI-1) in the left atria from sham-operated and rapidly-paced hearts. Rapid atrial pacing decreased the immunoreactive proteins of TFPI, TM and eNOS, while it increased that of PAI-1. Pre-administration of olmesartan prevented the decrease of TFPI, TM and eNOS by rapid pacing. Conversely, it prevented the increase of PAI-1. b: Immunoreactive protein levels of TFPI, TM, eNOS and PAI-1 (n=6, each). Olmesartan at doses > 1 mg/kg/day significantly increased TFPI, TM and eNOS protein levels in the rapidly-paced left atrium (* = p<0.05 vs. rapid pacing without the drug). The drug at an even lower dose of 0.3 mg/kg/day significantly decreased PAI-1 protein level (* = p<0.05 vs. rapid pacing without the drug).
C O P Y R I G H T J R A A S L I M I T E D R E P R O D U C T I O N P R O H I B I T E D
rat MAX-PO (MULTI) labelled polymer system (Nichirei Biosciences Inc.). Polyclonal anti-CD31 antibody from mouse (BD Biosciences Pharmingen) was used as a marker of endocardial cells.
Drug administration
In an olmesartan group, rats were fed ad libitum with diet containing olmesartan at doses of 0.3, 1 and 3 mg/kg/day for two weeks prior to the rapid pacing. The dosage has been determined on the basis that the diet containing the higher dose of 5 mg/kg/day has been known not to affect the BP and the heart rate in rats. 15 In a placebo group, rats were fed with the same diet without the drug.
Statistical analysis
Data are expressed as mean±SD. The mean values between the two groups were compared with unpaired t-tests. The mean values during drug administration were analysed using analysis of variance (ANOVA) and thereafter with the post-test for linear trend. Multiple comparisons with the placebo group were made using Bonferroni's modified t-test. Statistical significance was set at a p value < 0.05.
Results
Animal models
The administration of olmesartan at the doses of 0.3, 1, and 3 mg/kg/day did not significantly affect the heart weight and body weight of the rats as compared with control rats. The BP during the rapid pacing did not significantly differ between the groups (olmesartan group: 114±15/68±4 mmHg at 0.03, 116±12/70±5 mmHg at 1, and 114±12/66±5 mmHg at 3 mg/kg/day; control group 112±16/66±8 mmHg, N.S. n=10 in each). The heart rate during the rapid pacing was significantly not different between the groups (olmesartan group: 465±32 bpm at 0.03, 458±45 bpm at 1, and 448±36 bpm at 3 mg/kg/day; control group: 455 ± 35 bpm, N.S. n=10 in each).
Effects of olmesartan on TFPI, TM, eNOS, PAI-1 protein expression in atria
In control rats without rapid pacing, preadministration of olmesartan did not affect the expression of immunoreactive proteins of TFPI, TM, eNOS and PAI-1 in the left atrium. Figure 1a showed the representative recordings of the effects of olmesartan on the protein expression of TFPI, TM, eNOS and PAI-1 in the rapid pacing animal. While rapid atrial pacing for eight hours significantly decreased the concentrations of immunoreactive of TFPI, TM and eNOS proteins and increased the expression of PAI-1 as reported previously, 8, 9 olmesartan significantly attenuated the magnitude of all these effects caused by rapid pacing (figure 1b, TFPI: p<0.0001 for both ANOVA and post-test for linear trend; TM: ANOVA, p=0.0094, and post-test for linear trend, p=0.0016; eNOS: ANOVA, p=0.0068, and post-test Immunohistochemistry Figure 2 demonstrated the distribution of TFPI, TM, eNOS and PAI-1 proteins in the rapidlypaced left atrium with and without olmesartan at a dose of 3 mg/kg/day. As shown in our previous report and in others, 8, 9 TFPI, TM and eNOS were predominantly expressed in the endocardial cells of the left atrium and apparently stripped by the rapid pacing. The drug attenuated the extent of this stripping and preserved the expression of these three proteins (figure 2b to d and g to i). In contrast, PAI-1, was clearly expressed in the endocardial cells of the left atrium by rapid pacing and could not be detected in the absence of pacing. The drug decreased the level of expression of this protein as shown in figure 2e and j.
Effects of olmesartan on TM, TFPI, eNOS, PAI-1 mRNA expression in atria
To examine whether the effects of olmesartan on the protein expression were mediated by transcriptional regulation, we determined the effects of the drug at a dose of 1 mg/kg/day on the messenger ribonucleic (mRNA) expression of TFPI, TM, eNOS and PAI-1 in the rapidly-paced left atrium. Rapid pacing significantly decreased the mRNA level of TFPI and TM as in our previous study, 9 while it did not affect that of eNOS. In contrast, PAI-1 mRNA was significantly up-regulated by the rapid pacing. The effects of olmesartan on the mRNA levels are shown in figure 3 . While the drug did not alter the mRNA levels of TFPI, TM and eNOS, it significantly prevented the up-regulation of PAI-1 mRNA.
Discussion
The major findings of the present study were as follows: (1) the blockade AT 1 -receptor by olmesartan significantly prevented the downregulation of TFPI, TM and eNOS proteins in the atrial endocardium of rapidly paced rat hearts without alterations in their mRNA levels, and (2) it also prevented the up-regulation of PAI-1 proteins associated with the increase in the mRNA. These observations indicated that Angiotensin II (Ang II) could be involved in the atrial endocardial dysfunction caused by rapid pacing at both pre-and post-translational levels and that the blockade of Ang II signals would produce some beneficial effects in decreasing the likelihood of thrombus formation in the left atrium. fibrillating left atrium as well as in vessels. [7] [8] [9] 16 Rapid atrial pacing per se could impair the intrinsic antithrombotic function of the left atrium. The normal endocardial cells of the left atrium express antithrombotic molecules including eNOS, TFPI and TM, thereby controlling the local coagulation balance on the internal surface of the left atrium. However, these important molecules are known to be decreased by rapid atrial pacing in experimental studies. 8, 9 Moreover, one of the prothrombotic molecules, PAI-1, is known to be expressed in the atrial endocardium during atrial fibrillation. 8 Recently, one of the mechanisms of this endocardial dysfunction has been proposed to be oxidative stress produced in the left atrium by atrial fibrillation. 17, 18 Dudley et al. have demonstrated that O 2 .production was increased in the pig left atrium by atrial fibrillation, primarily via increased activity of reduced nicotinamide-adenine dinucleotide phosphate (NADPH) and xanthine oxidase. 17 This observation may draw a parallel to the mechanisms of atherosclerosis, and thereby propose a link between AF and local activation of the RAS, because Ang II is a potent stimulator of the NAD(P)H oxidase. 19 In the present study, we have examined the relationships between Ang II and the endocardial expression of TFPI, TM, eNOS and PAI-1, using a specific ARB, and demonstrated that the atrial endocardial dysfunction in atrial fibrillation was, at least in part, prevented by the blockade of AT 1 -receptor.
At the same time, the present results revealed the complexity of the endocardial dysfunction induced by rapid pacing and its association with Ang II. Our previous report demonstrated that rapid atrial pacing decreased the protein expression of TFPI and TM with decreases in their mRNA levels, suggesting possible regulation at a pretranslational level. Similarly, it increased PAI-1 protein expression in accordance with alterations in its mRNA level. However, the decrease in eNOS protein was not associated with changes in the mRNA level, which is also a new finding in the present study. These observations would imply that the endocardial dysfunction by atrial fibrillation could occur at pre-and posttranslational levels. Moreover, the preventive effects of AT 1 -receptor blockade were observed also at multiple levels. Olmesartan inhibited PAI-1 protein up-regulation along with the decrease in the mRNA level. In contrast, it prevented the down-regulation of TFPI, TM and eNOS protein without affecting their mRNA levels, suggesting the involvement of alterations in the turn-over and/or release of the proteins. Moreover, the dose-response relationships of olmesartan in the preventive effects were somewhat different between the four molecules investigated. The effects on PAI-1 protein were observed at the lowest dose of 0.3 mg/kg/day, while the effects on TFPI, TM and eNOS were observed at doses > 1 mg/kg/day. These observations might be plausible, because the former and the latter effects were mediated by different mechanisms in view of alterations in the mRNA.
In vascular endothelium, the preventive effects of ARBs on the endothelial dysfunction have been well known. 20, 21 ARBs have been reported to inhibit PAI-1 expression and also to increase eNOS expression in the vasculature. [22] [23] [24] Although knowledge regarding the effects on vascular TFPI and TM is limited, the present results could propose similar beneficial effects on the atrial endocardium as on the vascular endothelium.
Although it is as yet hypothetical that the preserved function of the atrial endocardium might lead to decreased incidence of thrombus formation in AF, the results from recent clinical trials might support this hypothesis. For example, the LIFE study using losartan has demonstrated that the incidence of stroke in AF patients was decreased by losartan significantly more than by atenolol, despite the absence in significant differences in BP and concurrent oral anticoagulation. 11 The result seems very reasonable in view of the present results, because oral anticoagulation and ARBs control the local coagulation balance through different mechanisms, i.e., by blood coagulability and from the endocardial antithrombotic functions. Our present study could thus propose a basis for a new paradigm of stroke prevention in AF patients. The concept of managing the local coagulation balance would deserve more clinical investigation, because it could augment the beneficial effects of oral anticoagulation without increasing major bleeding.
There are several limitations in the present study. First are the species differences, which might affect the involvement of Ang II and the drug sensitivity. Secondly, duration of atrial fibrillation might affect the degree of the endocardial dysfunction. Thirdly, it should be ascertained in future experiments whether local increase of Ang II really occurs in the fibrillating atrium, to understand in detail the relationships between RAS and endocardial dysfunction in the atrium. Although endocardial dysfunction in human atrial fibrillation requires further investigation, the present results could provide help in considering a new paradigm of managing local coagulation balance for preventing stroke in atrial fibrillation, which is an important problem for an ageing society. 
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